Summary
Gilead Sciences, Inc. (GILD) reported strong revenue growth in its 2009 10-K filing, reaching $7.01 billion, a significant increase driven primarily by its antiviral products, notably Truvada and Atripla, which together represented 69% of total revenues. The company's strategic acquisition of CV Therapeutics in April 2009 expanded its presence in the cardiovascular therapeutic area, adding Ranexa to its portfolio. Gilead also demonstrated a commitment to global health through its Access Program, providing HIV medications at reduced prices in developing countries. Despite robust sales, the company faced challenges including increased R&D expenses, competition in its key markets, and potential impacts from foreign currency fluctuations and healthcare reforms. The company highlighted its strong pipeline progress, particularly in HIV with the evaluation of new combination therapies. Gilead's financial position remained solid, with substantial cash reserves and a continued focus on stock repurchases. The company's outlook for 2010 anticipated continued growth, supported by updated product labels, evolving treatment guidelines, and expanded commercial efforts, while acknowledging the uncertainties presented by the macroeconomic environment.
Financial Highlights
52 data points| Revenue | $7.01B |
| Cost of Revenue | $1.60B |
| Gross Profit | $5.42B |
| SG&A Expenses | $946.69M |
| Operating Expenses | $3.48B |
| Operating Income | $3.53B |
| Interest Expense | $69.66M |
| Net Income | $2.64B |
| EPS (Basic) | $1.46 |
| EPS (Diluted) | $1.41 |
| Shares Outstanding (Basic) | 1.81B |
| Shares Outstanding (Diluted) | 1.87B |
Key Highlights
- 1Record total revenues of $7.01 billion in 2009, a 27% increase from 2008, primarily driven by strong sales of antiviral products Truvada and Atripla.
- 2Acquisition of CV Therapeutics in April 2009 significantly expanded Gilead's presence in the cardiovascular market with the addition of Ranexa.
- 3Antiviral products accounted for 90% of total product sales ($5.84 billion), with Truvada and Atripla being the key drivers.
- 4Royalty revenues increased significantly by 125% to $491.8 million, mainly due to increased Tamiflu sales by Roche.
- 5Research and Development expenses increased by 30% to $939.9 million, reflecting continued investment in pipeline development.
- 6The company maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $3.90 billion at year-end 2009.
- 7Gilead is facing ongoing patent litigation with Teva Pharmaceuticals regarding generic versions of its key HIV products, Truvada, Atripla, and Viread.